Syngene International Limited reported strong financial results for the quarter ended June 30, 2025 (Q1 FY26), led by higher revenue and improved margins.
For the quarter, the company’s revenue from operations rose 11% year-on-year (YoY) to ₹875 crore, compared to ₹790 crore in Q1 FY25. Reported revenue, including other income, stood at ₹892 crore, up 10% YoY.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) came in at ₹224 crore, growing 19% from ₹188 crore last year. The EBITDA margin improved to 25% from 23% YoY, driven by revenue growth and cost optimization.
Net profit (PAT) surged 59% to ₹87 crore from ₹54 crore in the same quarter last year. The PAT margin expanded to 10% from 7% YoY.
Key Financials: YoY comparison
| Metric | Q1 FY25 | Q1 FY26 | YoY Change (%) |
|---|---|---|---|
| Revenue from operations (₹ Cr) | 790 | 875 | ↑ 11% |
| Reported revenue (₹ Cr) | 808 | 892 | ↑ 10% |
| EBITDA (₹ Cr) | 188 | 224 | ↑ 19% |
| EBITDA margin (%) | 23 | 25 | ↑ 200 bps |
| Net profit (PAT) (₹ Cr) | 54 | 87 | ↑ 59% |
| PAT margin (%) | 7 | 10 | ↑ 300 bps |
Commenting on the results, Peter Bains, Managing Director and CEO, highlighted that the performance was in line with expectations, supported by continued conversion of pilot programs into longer-term contracts in the Research Services business and progress in the Biologics manufacturing division.
Deepak Jain, CFO, noted that the quarter’s profitability also benefitted from a tax credit, and the company maintained a strong balance sheet to invest in capabilities and technology.
Other business highlights included the successful completion of USFDA inspections, inauguration of a state-of-the-art peptide laboratory, and recognition by TIME and Statista as one of the world’s most sustainable companies.
